Loading clinical trials...
Loading clinical trials...
Effect of an Ellagitannin Rich Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects. A Double-blind, Cross-over, Dose-response, Randomized, Placebo-controlled Trial (The POMEcardio Study)
Conditions
Interventions
Pomegranate extract-first dose-Group A
Placebo-first dose-Group B
+6 more
Locations
1
Spain
UCAM (San Antonio Catholic University from Murcia)
Murcia, Murcia, Spain
Start Date
February 1, 2014
Primary Completion Date
August 1, 2014
Completion Date
December 1, 2014
Last Updated
April 14, 2015
NCT07472881
NCT07237750
NCT07460856
NCT07225426
NCT07423780
NCT07445503
Lead Sponsor
National Research Council, Spain
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions